Literature DB >> 14729609

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.

Zhigang C Wang1, Ming Lin, Lee-Jen Wei, Cheng Li, Alexander Miron, Gabriella Lodeiro, Lyndsay Harris, Sridhar Ramaswamy, David M Tanenbaum, Matthew Meyerson, James D Iglehart, Andrea Richardson.   

Abstract

Gene expression array profiles identify subclasses of breast cancers with different clinical outcomes and different molecular features. The present study attempted to correlate genomic alterations (loss of heterozygosity; LOH) with subclasses of breast cancers having distinct gene expression signatures. Hierarchical clustering of expression array data from 89 invasive breast cancers identified four major expression subclasses. Thirty-four of these cases representative of the four subclasses were microdissected and allelotyped using genome-wide single nucleotide polymorphism detection arrays (Affymetrix, Inc.). LOH was determined by comparing tumor and normal single nucleotide polymorphism allelotypes. A newly developed statistical tool was used to determine the chromosomal regions of frequent LOH. We found that breast cancers were highly heterogeneous, with the proportion of LOH ranging widely from 0.3% to >60% of heterozygous markers. The most common sites of LOH were on 17p, 17q, 16q, 11q, and 14q, sites reported in previous LOH studies. Signature LOH events were discovered in certain expression subclasses. Unique regions of LOH on 5q and 4p marked a subclass of breast cancers with "basal-like" expression profiles, distinct from other subclasses. LOH on 1p and 16q occurred preferentially in a subclass of estrogen receptor-positive breast cancers. Finding unique LOH patterns in different groups of breast cancer, in part defined by expression signatures, adds confidence to newer schemes of molecular classification. Furthermore, exclusive association between biological subclasses and restricted LOH events provides rationale to search for targeted genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729609     DOI: 10.1158/0008-5472.can-03-2570

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

2.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma.

Authors:  Jin Li; Lyndsay Harris; Harvey Mamon; Matthew H Kulke; Wei-Hua Liu; Penny Zhu; G Mike Makrigiorgos
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Apigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cells.

Authors:  Ivana Vrhovac Madunić; Josip Madunić; Maja Antunović; Mladen Paradžik; Vera Garaj-Vrhovac; Davorka Breljak; Inga Marijanović; Goran Gajski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-14       Impact factor: 3.000

5.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Authors:  Melinda L Telli; Kirsten M Timms; Julia Reid; Bryan Hennessy; Gordon B Mills; Kristin C Jensen; Zoltan Szallasi; William T Barry; Eric P Winer; Nadine M Tung; Steven J Isakoff; Paula D Ryan; April Greene-Colozzi; Alexander Gutin; Zaina Sangale; Diana Iliev; Chris Neff; Victor Abkevich; Joshua T Jones; Jerry S Lanchbury; Anne-Renee Hartman; Judy E Garber; James M Ford; Daniel P Silver; Andrea L Richardson
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

6.  Chromosomal changes in aggressive breast cancers with basal-like features.

Authors:  Wayne Yu; Yasmine Kanaan; Young Kyung Bae; Young-Kyung Baed; Edward Gabrielson
Journal:  Cancer Genet Cytogenet       Date:  2009-08

7.  Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas.

Authors:  Christine S Walsh; Seishi Ogawa; Daniel R Scoles; Carl W Miller; Norihiko Kawamata; Steven A Narod; H Phillip Koeffler; Beth Y Karlan
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.

Authors:  Yang Li; Lihua Zou; Qiyuan Li; Benjamin Haibe-Kains; Ruiyang Tian; Yan Li; Christine Desmedt; Christos Sotiriou; Zoltan Szallasi; J Dirk Iglehart; Andrea L Richardson; Zhigang Charles Wang
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

9.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Authors:  Jason I Herschkowitz; Xiaping He; Cheng Fan; Charles M Perou
Journal:  Breast Cancer Res       Date:  2008-09-09       Impact factor: 6.466

10.  Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.

Authors:  M Chehani Alles; Margaret Gardiner-Garden; David J Nott; Yixin Wang; John A Foekens; Robert L Sutherland; Elizabeth A Musgrove; Christopher J Ormandy
Journal:  PLoS One       Date:  2009-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.